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The frequency of high-risk human papillomavirus (hr-HPV) genotypes in patients with adenocarcinoma in situ (ACIS) with coexisting
cervical intraepithelial neoplasia (CIN), ACIS without coexisting CIN, and high-grade CIN (CIN II/III) was studied, in order to gain
more insight into the relation between hr-HPV infections and the development of coexisting squamous and glandular lesions. The
SPF10 LiPA PCR was used to detect simultaneously 25 different HPV genotypes in biopsies obtained from 90 patients with CIN II/III,
47 patients with ACIS without coexisting CIN, and 49 patients with ACIS and coexisting CIN. hr-HPV was detected in 84 patients
(93%) with CIN II/III, 38 patients (81%) with ACIS without CIN, and in 47 patients (96%) with ACIS and coexisting CIN. A total of 13
different hr-HPV genotypes were detected in patients with CIN II/III, and only five in patients with ACIS with/without coexisting CIN.
HPV 31, multiple hr-HPV genotypes, and HPV genotypes other than 16, 18, and 45 were significantly more often detected in patients
with CIN II/III, while HPV 18 was significantly more often detected in patients with ACIS with/without CIN. There were no significant
differences in the frequency of specific hr-HPV genotypes between patients with ACIS with or without coexisting CIN. In conclusion,
the frequency of specific hr-HPV genotypes is similar for patients with ACIS without CIN and patients with ACIS and coexisting CIN,
but is significantly different for patients with CIN II/III without ACIS. These findings suggest that squamous lesions, coexisting with high-
grade glandular lesions, are aetiologically different from squamous lesions without coexisting glandular lesions.
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A causal relation between high-risk human papillomavirus
(hr-HPV) infections and cervical cancer has been documented
in the literature beyond reasonable doubt (Bosch et al, 2002;
Wright et al, 2002). High-risk human papillomavirus can be
detected in almost 100% of squamous carcinomas and adenocar-
cinomas of the uterine cervix (Walboomers et al, 1999; Pirog
et al, 2000). Numerous studies have suggested that the develop-
ment of squamous cervical carcinoma is preceded by cervical
intraepithelial neoplasia (CIN) (Wright et al, 2002; Bosch et al,
2002).
The frequency of hr-HPV genotypes in CIN lesions has been
studied previously and its detection rate rises with increasing
severity of the CIN lesion (Bekkers et al, 2002a; Bosch et al, 2002;
Wright et al, 2002). Only limited studies are available on the
frequency of hr-HPV genotypes in premalignant glandular lesions
and the number of patients in most studies is rather low
(see Table 1) (Colgan and Lickrish, 1990; Leary et al, 1991;
Higgins et al, 1992; Duggan et al, 1995; Anciaux et al, 1997;
McLachlin et al, 1997; Pirog et al, 2000; Riethdorf et al, 2000,
2002; Madeleine et al, 2001). High-risk human papillomavirus
was detected in 66–100% of patients with ACIS (Anciaux et al,
1997; Riethdorf et al, 2000). Approximately 48% of all women
diagnosed with ACIS have coexisting squamous lesions
(Colgan and Lickrish, 1990; Leary et al, 1991; Higgins et al, 1992;
Duggan et al, 1995; Anciaux et al, 1997; McLachlin et al, 1997;
Pirog et al, 2000; Riethdorf et al, 2000, 2002; Madeleine et al, 2001),
but the frequency of specific hr-HPV genotypes in patients
with ACIS has not been studied in relation with the presence or
absence of coexisting CIN lesions. In this study, the frequency of
specific hr-HPV genotypes in patients with ACIS and coexisting
CIN is compared with its frequency in patients with ACIS
without coexisting CIN, and patients with CIN without ACIS, in
order to gain more insight into the relation between hr-HPV
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ypatients diagnosed with ACIS between 1988 and 2000 were
identified. No histopathological material was left for further study
of nine patients, and six patients had a histopathological diagnosis
of invasive carcinoma within 1 month of the diagnosis of ACIS. Of
the remaining 105 patients, the histopathological slides of a
biopsy-, cone-, or hysterectomy specimen were re-examined
independently, by three experienced gynaecopathologists (JB,
AWvT, and MM). Complete agreement on the diagnosis of ACIS
was reached in 96 patients (91%), according to the criteria of
Brown and Wells. The criteria of Brown and Wells take
architectural (glandular irregularity and complexity) and cytolo-
gical criteria (nuclear enlargement, hyperchromasia, pseudostra-
tification of nuclei, increased or abnormal mitoses) into account
(Wells and Brown, 1986). The three pathologists reached no
consensus on the diagnosis of ACIS in nine patients, and these
patients were excluded.
Coexisting squamous intraepithelial lesions were detected
and confirmed by consensus of the three pathologists (JB, AWvT,
MM) in the slides of 49 of the 96 patients (51%); 35 patients
(71%) had coexisting CIN 3 (severe dysplasia, or carcinoma in
situ), eight patients (16%) had coexisting CIN 2 (moderate
dysplasia), and six patients (12%) had coexisting CIN 1
(mild dysplasia). In 41 of these 49 patients (84%), CIN and
ACIS were diagnosed in the same slide/section, and hr-HPV
detection was carried out on adjacent sections, containing
both the squamous and glandular lesion. In eight patients, CIN
was diagnosed in a different slide than in which ACIS
was diagnosed and on which hr-HPV detection was performed.
Five of these eight patients had coexisting CIN I, two
had coexisting CIN II, and one had coexisting CIN III. The mean
age of the 96 patients was 38.3 years (28–73) at the time of the
diagnosis.
A cervical scrape preceding the diagnosis of ACIS less than 6
months was made in 43 of the 49 patients (88%) with ACIS
and coexisting CIN, and in 40 of the 47 patients (85%) with
ACIS without coexisting CIN. The cervical scrape indicated a high-
grade glandular (moderate atypia–ACIS), a high-grade squamous
lesion (moderate dysplasia–CIS), or both in, respectively, 13
(30%), 15 (35%), and 13 (30%) patients with ACIS and coexisting
CIN, and in, respectively, 24 (60%), four (10%), and eight (20%)
patients with ACIS without coexisting CIN. The remaining six
patients had only mild atypia of glandular cells in the cervical
scrape.
Squamous lesions
A control group of 90 patients consisted of patients who consulted
the colposcopy clinic at the UMC between 1997 and 1999 and who
were diagnosed with high-grade CIN in the biopsy specimen of a
large-loop excision of the transformation zone. All slides were
reviewed by an experienced gynaecopathologist (JB), and the
diagnosis of high-grade CIN was confirmed. Of these 90 patients,
18 patients (20%) were diagnosed with moderate dysplasia (CIN
II), 36 patients (40%) with severe dysplasia (CIN III), and 36
patients (40%) with carcinoma in situ (CIN III). The mean age at
the time of diagnosis was 37.6 years (28–59).
A cervical scrape preceding the diagnosis of CIN II/III less than
6 months was taken of all 90 patients. The cervical scrape indicated
a high-grade squamous lesion in 80 patients (89%), a high-grade
glandular and squamous lesion in one patient (1%), and low-grade
squamous lesions in nine patients (10%).
Taking the preceding cervical scrapes of all patients with ACIS
and CIN II/III together, the cervical scrape indicated a high-grade
glandular lesion in 37 patients (21%), a high-grade squamous
lesion in 99 patients (57%), both in 22 patients (13%), and only
low-grade lesions in 15 patients (9%).
HPV detection
A3 - mm section of the histopathological specimens, on which ACIS
and/or CIN II/III was diagnosed, was taken for HPV analysis. In 41
of the 49 patients with ACIS and coexisting CIN, HPV detection
was carried out on a section containing both the glandular and
squamous lesion. HPV detection was performed using a broad-
spectrum short-fragment polymerase chain reaction (SPF10 PCR)
as previously described (Kleter et al, 1998, 1999; Melchers et al,
1999; Quint et al, 2001; Bekkers et al, 2002b). In case of a positive
PCR, subsequent genotyping was performed via a reverse
hybridisation line probe assay (LiPA), allowing for simultaneous
typing of 25 HPV genotypes, including hr-HPV genotypes 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. This SPF10 LiPA PCR
HPV detection method is highly sensitive, specific and reprodu-
cible and has been clinically validated (Kleter et al, 1998, 1999;
Melchers et al, 1999; Pirog et al, 2000; Quint et al, 2001). If more
than one hr-HPV genotype was detected with the SPF10 LiPA PCR
in a single sample of an individual patient, that patient was
considered to be infected with multiple hr-HPV genotypes.
Table 1 Summary of all studies since 1990 with more than 20 ACIS patients in relation with hr-HPV and/or coexisting CIN
Author and year Patients (n) hr-HPV pos HPV 16 HPV 18 Coexisting CIN
Riethdorf et al (2002) 42 32 22 10 ND
(76%) (53%) (24%)
Madeleine et al (2001) 82 71 32 43 ND
(87%) (39%) (52%)
Riethdorf et al (2000) 33 29 21 8 14
(88%) (64%) (24%) (42%)
Pirog et al (2000) 23 23 10 6 9
(100%) (43%) (26%) (39%)
Anciaux et al (1997) 21 16 6 10 9
(76%) (29%) (47%) (43%)
Duggan et al (1994) 37 23 8 15 ND
(66%) (23%) (43%)
Higgins et al (1992) 42 39 13 28 22
(95%) (31%) (67%) (52%)
Leary et al (1991) 30 21 10 11 15
(70%) (33%) (37%) (50%)
Bekkers et al (present study) 96 85 39 41 49
(89%) (41%) (43%) (51%)
ACIS¼adenocarcinoma in situ; hr-HPV¼ high-risk human papillomavirus; CIN¼cervical intraepithelial neoplasia; HPV¼human papillomavirus; ND¼not documented.
ACIS, CIN, or ACIS and CIN and HPV infections
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The frequency of specific hr-HPV genotypes in patients with ACIS
without coexisting CIN, ACIS with coexisting CIN, and CIN II/III
without ACIS were compared. The frequency of specific hr-HPV
genotypes was also investigated in relation with the suspicion of a
high-grade glandular and/or high-grade squamous lesion in the
preceding cervical scrape. Statistical analysis including w
2 tests and
independent t-tests was performed, considering all values of
Po0.05 to be significant.
RESULTS
High-risk human papillomavirus genotypes were detected
in 93% of the patients with CIN II/III, 81% of the patients with
ACIS without coexisting CIN, and in 96% of the patients with
ACIS and coexisting CIN. Figure 1 shows that HPV 31 and
multiple hr-HPV genotypes were significantly more often detected
in patients with CIN II/III, while HPV 18 was significantly more
often detected in patients with ACIS (with or without coexisting
CIN). Among patients with CIN II/III, 13 different hr-HPV
genotypes were detected, compared with only five different hr-
HPV genotypes in patients with ACIS with or without coexisting
CIN.
HPV 16 was the most frequently detected HPV genotype in
patients with CIN II/III (54%), while both HPV 16 and 18 showed a
high frequency of, respectively, 41 and 43% in all patients with
ACIS (see Figure 1). HPV 16 or 18 were present in 79% of all
patients with ACIS (five patients had a double infection with HPV
16 and 18), and in 61% of the patients with CIN II/III (one patient
had a double infection with HPV 16 and 18).
Table 2 shows that there were no significant differences in the
frequency of HPV 16, 45, and hr-HPV-negative patients between
patients with CIN II/III and patients with ACIS and coexisting CIN.
The frequency of HPV 18 was significantly lower, and the
frequency of HPV 31, multiple hr-HPV, and hr-HPV genotypes
other than HPV 16, 18, 31, and 45 was significantly higher in
patients with CIN II/III compared with patients with ACIS and
coexisting CIN. This means that the frequency of HPV 18 is
significantly higher in CIN lesions coexisting with ACIS than in
solitary CIN lesions.
Table 3 shows that there were no significant differences in the
frequency of HPV 16, 18, 31, 45, multiple hr-HPV, and other hr-
HPV genotypes between patients with ACIS without coexisting
CIN and patients with ACIS and coexisting CIN. The number of hr-
HPV-negative patients was significantly higher in patients with
ACIS without coexisting CIN.
Among the patients with ACIS and coexisting CIN, there were
no significant differences in the frequency of specific hr-HPV
genotypes regarding the different degrees of coexisting CIN.
The mean age of the patients with ACIS without CIN was 40.1























































CIN II/III   ACIS
Figure 1 Relative frequency of specific hr-HPV genotypes in patients
with CIN II/III (90 patients) and patients with ACIS (96 patients). *Po0.05,
**Po0.01, ***Po0.001.
Table 3 Frequency of hr-HPV genotypes in patients with ACIS with coexisting CIN compared with
patients with ACIS without coexisting CIN





16 19 (39%) 20 (43%) NS
18 23 (47%) 18 (38%) NS
31 0 (0%) 0 (0%) NS
45 5 (10%) 2 (4%) NS
Other 2 (4%) 1 (2%) NS
Multiple 2 (4%) 3 (6%) NS
Total hr-HPV positive 47 (96%) 38 (81%) w
2¼6.07, Po0.02
hr-HPV negative 2 (4%) 9 (19%) w
2¼6.63, Po0.01
ACIS¼adenocarcinoma in situ; hr-HPV¼ high-risk human papillomavirus; CIN¼cervical intraepithelial neoplasia; NS¼not
significant.
Table 2 Frequency of hr-HPV genotypes in patients with CIN II/III compared with patients with ACIS and
coexisting CIN





16 49 (54%) 19 (39%) NS
18 7 (8%) 23 (47%) w
2¼26.49, Po0.001
31 15 (17%) 0 (0%) w
2¼8.38, Po0.01
45 3 (3%) 5 (10%) NS
Other 34 (38%) 2 (4%) w
2¼19.73, Po0.001
Multiple 26 (29%) 2 (4%) w
2¼12.48, Po0.001
Total hr-HPV positive 84 (93%) 47 (96%) NS
hr-HPV negative 6 (7%) 2 (4%) NS
ACIS¼adenocarcinoma in situ; hr-HPV¼ high-risk human papillomavirus; CIN¼cervical intraepithelial neoplasia; NS¼not
significant.
ACIS, CIN, or ACIS and CIN and HPV infections
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ywas 36.3 years (t¼2.32, Po0.05). There was no difference between
the mean age of the total group of patients with ACIS and the
patients with CIN II/III (38.2 and 37.6 years, respectively).
Within the group of patients with CIN II/III, there were no
significant differences in the frequency of HPV 16, 18, 31, and 45,
multiple hr-HPV, other hr-HPV genotypes, or hr-HPV-negative
patients between patients with moderate dysplasia, severe dyspla-
sia, or carcinoma in situ. Multiple hr-HPV genotypes were detected
in, respectively, 22, 28, and 33% of these patients.
High-risk human papillomavirus was detected in 33 of
the 37 patients (89%) with a cervical scrape that indicated a
high-grade glandular lesion, in 92 of the 99 patients (93%)
with a cervical scrape that indicated a high-grade squamous
lesion, in all 22 patients (100%) with a cervical scrape that
indicated both a high-grade glandular and squamous lesion, and in
13 of the 15 patients (87%) with a cervical scrape that indicated
only a low-grade lesion. There were no significant differences in
the frequency of HPV 16, 18, 31, 45, multiple or other HPV
genotypes regarding the presence or absence of a suspicion of a
high-grade squamous and/or glandular lesion in the cervical
scrapes.
DISCUSSION
The number of patients with ACIS and coexisting CIN lesions
among all patients with ACIS in this study is similar to the
numbers reported in the literature (Table 1). No significant
differences in the frequency of different hr-HPV genotypes
were observed between patients with ACIS with coexisting CIN,
and patients with ACIS without coexisting CIN, as has been
reported previously (Anciaux et al, 1997; Riethdorf et al, 2000;
Zaino, 2002). However, significant differences in the frequency of
HPV 18, HPV 31, multiple hr-HPV genotypes, and hr-HPV
genotypes other than HPV 16, 18, 31, and 45 were observed
between patients with CIN II/III and patients with ACIS, either
with or without coexisting CIN. One may hypothesise that
coexisting glandular and squamous lesions share a common
aetiology, different from solitary squamous lesions, under the
influence of specific hr-HPV genotypes, as has been previously
described for squamous lesions (Burghardt and Ostor, 1983;
Park et al, 1998; Bekkers et al, 2002b). Indeed, in 41 of
the 49 patients (84%) in the present study the ACIS lesion was
adjacent to the coexisting squamous lesion. Furthermore, Colgan
and Lickrish (1990) found no differences in the linear extend,
circumferential extend, multifocality, or the co-presence of
invasive adenocarcinoma between patients with ACIS without
CIN and ACIS with coexisting CIN lesions. These observations
seem to support the hypothesis that ACIS and coexisting CIN
lesions share a common aetiology.
Only five different hr-HPV genotypes (HPV 16, 18, 33, 45, 58)
were detected in patients with ACIS (of which HPV 33 and 58 in
o2% of the patients), compared with 13 different hr-HPV
genotypes in patients with CIN II/III. Other authors also found a
limited number of hr-HPV genotypes (three to seven) among
patients with ACIS (Pirog et al, 2000; Madeleine et al, 2001).
This may suggest that only certain hr-HPV genotypes are
able to infect and/or induce lesions in the glandular mucosa.
This fact may be the reason for the significantly lower
detection rate of multiple hr-HPV genotypes, and the significantly
higher detection rate of HPV 18 in the cervix of patients with
ACIS. However, higher rates (13–22%) of multiple hr-HPV
infections among patients with ACIS have been described in the
literature (Pirog et al, 2000; Madeleine et al, 2001). The lower
rate of multiple hr-HPV genotypes in the present study is probably
the result of the very restrictive diagnostic criteria, and the
consensus agreement by three pathologists, that was used to
diagnose ACIS.
The high frequency of a single hr-HPV genotype in patients with
ACIS compared with patients with CIN II/III may reflect the
monoclonal aspect of the ACIS lesion, as is often the case in
invasive carcinomas (Walboomers et al, 1999). Patients with
(squamous) CIS in this study showed a higher prevalence (33%) of
multiple hr-HPV genotypes, as well as a higher number of different
hr-HPV genotypes (12), which may be regarded as another
indication that ACIS lesions may have a biologic behaviour and/
or aetiology that is different from squamous in situ lesions
(Schoolland et al, 2002).
The number of hr-HPV-negative patients with ACIS without
CIN in this study was significantly higher than in patients with
ACIS and coexisting CIN. ACIS may be a precursor of different
subtypes of invasive adenocarcinoma (like small cell or endome-
trioid adenocarcinoma) that have a lower or no prevalence of hr-
HPV (Lee, 1999; Pirog et al, 2000; Schoolland et al, 2002). These
subtypes are rare, and distinction on a biopsy with only ACIS
proved to be difficult (Lee, 1999; Schoolland et al, 2002). It is
possible that these hr-HPV-negative subtypes of ACIS are less
often associated with coexisting CIN, resulting in a higher rate of
hr-HPV-negative patients among patients with ACIS without CIN.
The significant difference in age between patients with ACIS
without CIN and patients with ACIS with coexisting CIN, in which
the latter are younger, has been described previously (Colgan and
Lickrish, 1990; Pirog et al, 2000). Different explanations for this
age difference are possible. Firstly, the lesions in patients with
ACIS and coexisting CIN may show a faster progression, leading to
detection at a younger age. This has been described previously for
HPV 18-related lesions (Barnes et al, 1988), but we did not find a
difference in HPV 18 prevalence between patients with ACIS alone
or ACIS and coexisting CIN. Secondly, the involvement of the
squamous epithelium may be the reason for the detection of ACIS
with coexisting CIN at a younger age, since ecto-cervical lesions
are more easily detected. Thirdly, it may be a coincidental
finding especially since we did not find a difference in mean age
between patients with CIN II/III and the total group of patients
with ACIS.
There was no significant difference in the overall sensitivity of
the preceding cervical scrape for the detection of either ACIS or
CIN II/III in the present study (respectively 93 and 90%). The
observed sensitivity to detect ACIS was higher than reported in the
literature (Lee, 1999; Schoolland et al, 2002). However, these
studies used cervical scrapes from a cervical cancer screening
programme, while in the present study several patients had more
than one preceding cervical scrape taken, which may have alerted
the pathologist, leading to the higher sensitivity.
We did not find a relation between the presence of certain
hr-HPV genotypes in the biopsy, and the sensitivity of the cervical
scrape in detecting ACIS and/or CIN II/III lesions. This indicates
that the detection of a lesion in the cervical scrape is not influenced
by the genotype of hr-HPV infecting that lesion.
In conclusion, patients with ACIS have significantly more
often HPV 18 infections, while patients with CIN II/III have
significantly more often infections with HPV 31, HPV genotypes
other than 16, 18, 31, and 45, and multiple hr-HPV genotypes. The
detection of high-grade glandular and/or squamous lesion by
cervical scrapes is not influenced by the hr-HPV genotype
associated with the lesion. Among patients with ACIS, patients
with coexisting CIN lesions tend to be younger, but they have a
similar frequency of different hr-HPV genotypes than patients with
ACIS without CIN, while the frequency of specific hr-HPV
genotypes differs significantly from those of patients with CIN
II/III without ACIS. These findings suggest that squamous lesions,
coexisting with high-grade glandular lesions, are aetiologically
different from squamous lesions without coexisting glandular
lesions. The clinical implication of these findings needs further
study.
ACIS, CIN, or ACIS and CIN and HPV infections
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